Bayview Acquisition Corp
BAYANasdaq
$12.14
↑ +1.2%Jul 6 close · end-of-day
Price
1Y↑ +8.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$33.2M
Enterprise Value
$33.2M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$308,660.00
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
5.0%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
+9.2%
Earnings
Next earnings · estimated2026-08-14
BAYA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$1.0M | -$986,503.00 |
| Net income | $1.8M | $202,599.00 |
| Diluted EPS | — | — |
| Operating cash flow | -$488,688.00 | -$49,491.00 |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$121,504.00 | -$273,029.00 | -$473,701.00 | -$270,459.00 | -$279,892.00 | -$218,940.00 | -$217,212.00 | -$471,513.00 |
| Net income | $592,289.00 | $583,558.00 | -$18,248.00 | $143,915.00 | $114,161.00 | -$17,903.00 | -$37,574.00 | -$367,344.00 |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$106,324.00 | -$76.00 | -$131,852.00 | -$41,019.00 | -$1,926.00 | -$12,333.00 | $5,787.00 | $6,058.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
- 3d agoAspen Ideas: Bayer EVP Matthias Berninger Overviews $20 Billion+ U.S. Investmentfinance.yahoo.com
- 3d agoBayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trialsfinance.yahoo.com
- 3d agoGSK shelves cough drug acquired in $2B dealbiopharmadive.com
Jul 14, 2026
- 6d agoORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayerfinance.yahoo.com
- 6d agoSabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farmingfinance.yahoo.com
- 6d agoAdvancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscapefinance.yahoo.com
Jul 10, 2026
- 10d agoSector Update: Financial Stocks Rise Friday Afternoonfinance.yahoo.com
- 10d agoBayer banks €3bn in Apollo contraceptives division dealpharmaceutical-technology.com
- 10d agoSector Update: Financial Stocks Rise Pre-Bell Fridayfinance.yahoo.com
- 10d agoBayer (XTRA:BAYN) Could Be 21% Undervalued Following Glyphosate Backlashfinance.yahoo.com
- 10d agoCan Bayer (XTRA:BAYN) Stay Cheap After An 83% Rally?finance.yahoo.com
- 10d agoBayer Sells $3.4 Billion Stake in Contraceptives Arm to Apollofinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.